⟵ Back to Search Results
BGB-283/PD-0325901-AU-001

Recruiting

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Beigene Study ID info

BGB-283/PD-0325901-AU-001

ClinicalTrials.gov ID info

NCT03905148

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents